PITTSBURGH, July 18, 2025 /PRNewswire/ – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, today announced its participation in the National Medical Association (NMA) Annual Convention and Scientific Assembly, being held from July 19-23, 2025, in Chicago, IL. Attendees are invited to visit MolecuLight at Booth #800 to learn how the MolecuLightDX® multimodal imaging platform is contributing to more equitable wound care.
MolecuLight “Lights the Way to Equitable Wound Care” at National Medical Association Conference (CNW Group/MolecuLight)
The NMA Annual Convention and Scientific Assembly is acclaimed as the nation’s premier forum on medical science and African American health, gathering healthcare providers to discuss critical topics, including the role of novel technologies in advancing healthcare equity. MolecuLight is eager to demonstrate how its innovative and inclusive imaging technology can “Light the Way to Equitable Wound Care” by providing objective, real-time information on bacterial presence, wound measurement, and skin temperature changes for all patients. These clinical insights support precise treatment and enhanced wound infection management, crucial for improving healthcare equity and combating the disproportionately poor healing outcomes faced by African American patients1. Clinical signs and symptoms of infection, such as erythema, are often missed by standard of care in patients with dark skin tones. Studies show 12x more wounds containing high bacterial loads are detected in dark skin2 using MolecuLight, and MolecuLight-informed care has been associated with an 11% reduction in amputations3.
“The National Medical Association is deeply committed to improving access to care and reducing health disparities, especially for minority communities and those impacted by chronic conditions like diabetes,” says Dr. Johnathan Johnson, a distinguished member of the NMA and Founder and Surgical Director for Comprehensive Woundcare Services in Washington, DC. “Wounds in patients with complicated conditions can lead to mortality rates even higher than some cancers, making effective wound care a critical focus. MolecuLight’s advanced imaging technology offers a powerful tool to address these challenges by providing real-time, objective information at the point of care. This is essential for preventing severe complications and ultimately saving lives, aligning perfectly with the NMA’s mission to advance health equity and improve patient outcomes.”
“We are incredibly proud to showcase the growing body of evidence demonstrating how MolecuLight’s technology supports equitable wound care practices,” says Anil Amlani, CEO of MolecuLight. “Our devices provide vital visual data for patients with all skin tones at the point of care, helping to standardize wound assessment and optimize patient outcomes across diverse populations. We are committed to empowering clinicians with the tools they need to deliver the highest standard of care.”
MolecuLight will highlight key clinical evidence at the conference, including peer-reviewed publications and compelling statistics that illustrate the impact of its integrated platform in improving wound care among diverse patient populations.
|
________________________________ |
|
1 Tan T, Armstrong DG, Concha-Moore CC, et al. Association between race/ethnicity and the risk of amputation of lower extremities among medicare beneficiaries with diabetic foot ulcers and diabetic foot infections: BMJ Open Diabetes Research & Care 2020;8:e001328. |
|
2 Johnson J, Johnson AR Jr, Andersen CA, et al. Skin Pigmentation Impacts the Clinical Diagnosis of Wound Infection: Imaging of Bacterial Burden to Overcome Diagnostic Limitations. J Racial Ethn Health Disparities. 2024 Apr;11(2):1045-1055. |
|
3 Price N. Routine Fluorescence Imaging to Detect Wound Bacteria Reduces Antibiotic Use and Antimicrobial Dressing Expenditure While Improving Healing Rates: Retrospective Analysis of 229 Foot Ulcers. Diagnostics (Basel). 2020;10(11). |
About MolecuLight Corp.
MolecuLight Corp. is a privately owned medical imaging company with a global presence that manufactures the MolecuLight i:X® and DX® wound imaging devices. These are the only commercially available point-of-care imaging devices with Class II FDA-clearance for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.
About the National Medical Association (NMA)
The National Medical Association (NMA) is the largest and oldest national organization representing African American physicians and health professionals in the United States. The NMA is committed to improving the quality of health among racial and ethnic minority populations through its membership, professional development, community education, advocacy, research, and partnerships.
SOURCE MolecuLight